[Results of the Hamburg ovarian blastoma study].
A randomized chemotherapy trial is forthwith reported on, in which therapy A (vincristine/ifosfamide/tegafur) was compared with therapy B (fluorouracil/trofosfamide/methotrexate/melphalan). Both patient groups received trofosfamide and oral progesterone as maintenance treatment until the end of the second therapy year. Forty-six patients were randomized into group A, 63 into group B. The evaluation of the survival curves suggests a division of the patients into 3 groups with different mortality risks.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005860:Germany, West; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008558:Melphalan / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D011897:Random Allocation; D005641:Tegafur / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D005641:Tegafur; D014750:Vincristine; D003520:Cyclophosphamide; C003726:trofosfamide; D008558:Melphalan; D005472:Fluorouracil; D007069:Ifosfamide; D008727:Methotrexate
Ergebnisse der Hamburger Ovarialblastom-Studie.